836 related articles for article (PubMed ID: 18037451)
1. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
2. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.
Raffa RB; Friderichs E; Reimann W; Shank RP; Codd EE; Vaught JL
J Pharmacol Exp Ther; 1992 Jan; 260(1):275-85. PubMed ID: 1309873
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations.
Munro G
Eur J Pharmacol; 2009 Mar; 605(1-3):95-102. PubMed ID: 19168051
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
5. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
6. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
[TBL] [Abstract][Full Text] [Related]
7. Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats.
Obata H; Kimura M; Nakajima K; Tobe M; Nishikawa K; Saito S
J Pharmacol Exp Ther; 2010 Sep; 334(3):1059-65. PubMed ID: 20558774
[TBL] [Abstract][Full Text] [Related]
8. Antihypersensitivity effects of tramadol hydrochloride in a rat model of postoperative pain.
Kimura M; Obata H; Saito S
Anesth Analg; 2012 Aug; 115(2):443-9. PubMed ID: 22575568
[TBL] [Abstract][Full Text] [Related]
9. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
10. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
11. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
Honore P; Donnelly-Roberts D; Namovic MT; Hsieh G; Zhu CZ; Mikusa JP; Hernandez G; Zhong C; Gauvin DM; Chandran P; Harris R; Medrano AP; Carroll W; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1376-85. PubMed ID: 16982702
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute and chronic tramadol on [3H]-5-HT uptake in rat cortical synaptosomes.
Giusti P; Buriani A; Cima L; Lipartiti M
Br J Pharmacol; 1997 Sep; 122(2):302-6. PubMed ID: 9313939
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the antinociceptive effect of systemic administration of tramadol and dexmedetomidine combination on rat models of acute and neuropathic pain.
Guneli E; Karabay Yavasoglu NU; Apaydin S; Uyar M; Uyar M
Pharmacol Biochem Behav; 2007 Nov; 88(1):9-17. PubMed ID: 17651791
[TBL] [Abstract][Full Text] [Related]
14. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
Zhao M; Wang JY; Jia H; Tang JS
Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416
[TBL] [Abstract][Full Text] [Related]
15. Increased tumor necrosis factor-alpha and prostaglandin E2 concentrations in the cerebrospinal fluid of rats with inflammatory hyperalgesia: the effects of analgesic drugs.
Bianchi M; Martucci C; Ferrario P; Franchi S; Sacerdote P
Anesth Analg; 2007 Apr; 104(4):949-54. PubMed ID: 17377112
[TBL] [Abstract][Full Text] [Related]
16. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
[TBL] [Abstract][Full Text] [Related]
17. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
18. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
Leánez S; Hervera A; Pol O
Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
[TBL] [Abstract][Full Text] [Related]
19. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM
J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
